Phase II year
2010
(last award dollars: 2011)
Phase II Amount
$1,419,863
Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from primary mouse blood stem cells. Phase I of this project included applying this technology to generate human cell lines. In addition, the project included testing a non-viral method to generate the stem cell lines from mice. Phase II of the project will entail optimizing large-scale production of protein transduced long-term hematopoietic stem cells from human cells that are resistant to HIV infection for eventual testing in larger animals and human clinical trials.
Public Health Relevance: This project seeks to optimize a novel method to generate large amounts of human blood stem cells for clinical use in the prevention and treatment of HIV infection. Once this method has been validated for large-scale production, the long-term goal for benefiting public health will be to use this system to generate HIV resistant cells in infected individuals or in populations that are at-risk for acquiring the HIV virus.
Thesaurus Terms: "0-11 Years Old; 21+ Years Old; Aids Virus; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Adult; Animal Model; Animal Models And Related Studies; Animals; Blood; Blood Cells; Blood Precursor Cell; Bone Marrow Stem Cell; Bone Marrow Stem Cell Transplantation; Bone Marrow Transplant; Bone Marrow Transplantation; C-C Ckr-5 Gene; C-C Chemokine Receptor Type 5 Gene; Cc-Ckr-5 Gene; Ccckr5 Gene; Ccr-5 Gene; Ccr5; Ccr5 Gene; Cd195 Antigen Gene; Chemr13 Gene; Ckr-5 Gene; Ckr5 Gene; Cmkbr5 Gene; Cancers; Cell Line; Cell Lineage; Cell Lines, Strains; Cell Surface; Cellline; Cells; Chemokine (C-C) Receptor 5 Gene; Child; Child Youth; Children (0-21); Chimera Protein; Chimeric Proteins; Clinical; Clinical Trials; Clinical Trials, Unspecified; Development; Engraftment; Fusion Protein; Generations; Genetic; Goals; Grafting, Bone Marrow; Hiv; Hiv Infections; Hiv-1 Fusion Co-Receptor Gene; Htlv-Iii; Htlv-Iii Infections; Htlv-Iii-Lav Infections; Hematopoietic Cell Tumor; Hematopoietic Malignancies; Hematopoietic Neoplasms; Hematopoietic Neoplasms Including Lymphomas; Hematopoietic Tumor; Hematopoietic And Lymphoid Cell Neoplasm; Hematopoietic And Lymphoid Neoplasms; Hematopoietic Stem Cells; Hematopoietic, Including Myeloma; Heterograft; Human; Human Cell Line; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type Iii; Human T-Cell Lymphotropic Virus Type Iii; Human T-Lymphotropic Virus Type Iii; Human, Adult; Human, Child; Human, General; Immune; Immunodeficiency Disorder; Immunodeficiency Syndrome; Immunologic Deficiency Syndromes; Immunological Deficiency Syndromes; In Vitro; Individual; Investigators; Lav-Htlv-Iii; Lentivirinae; Lentivirus; Lymphadenopathy-Associated Virus; Malignant Hematopoietic Neoplasm; Malignant Neoplasms; Malignant Tumor; Mammals, Mice; Man (Taxonomy); Man, Modern; Marrow; Marrow Transplantation; Methods; Mice; Modification; Mother Cells; Murine; Mus; Patients; Peripheral Blood Cell; Phase; Phenotype; Populations At Risk; Prevention; Production; Progenitor Cell Transplantation; Progenitor Cells; Progenitor Cells, Hematopoietic; Programs (Pt); Programs [publication Type]; Proteins; Public Health; Radiation; Receptor Protein; Recombinants; Research; Research Personnel; Researchers; Resistance; Reticuloendothelial System, Blood; Sbir; Sbirs (R43/44); Safety; Small Business Innovation Research; Small Business Innovation Research Grant; Source; Stem Cell Transplantation; Stem Cell Transplant; Stem Cells; Subfamily Lentivirinae; System; System, Loinc Axis 4; T-Cells; T-Lymphocyte; T-Lymphotropic Virus Type Iii Infections, Human; Technology; Testing; Therapeutic; Thymus-Dependent Lymphocytes; Transduction Gene; Translating; Translatings; Transplantation; Transplantation, Heterologous; Vector Mediated Transfer Genes; Viral; Virus-Hiv; Virus-Lenti; Work; Xenograft; Xenograft Procedure; Xenotransplantation; Abstracting; Adult Human (21+); Base; Blood Cancer; Cell Type; Children; Clinical Applicability; Clinical Application; Clinical Investigation; Cultured Cell Line; Gene Product; Hypoimmunity; Immune Deficiency Disorder; Immunodeficiency; In Vivo; Language Translation; Large Scale Production; Macrophage; Malignancy; Model Organism; Neoplasm/Cancer; New Approaches; New Technology; Novel; Novel Approaches; Novel Strategies; Novel Strategy; Phase 2 Study; Pluripotency; Pre-Clinical; Preclinical; Programs; Public Health Medicine (Field); Public Health Relevance; Rapid Growth; Ray (Radiation); Receptor; Reconstitute; Reconstitution; Resistant; Safety Testing; Thymus Derived Lymphocyte; Tool; Transplant; Youngster"